3-(benzyloxy)cyclobutane-1-carbaldehyde | 156865-33-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(benzyloxy)cyclobutane-1-carbaldehyde
• 英文别名: 3-phenylmethoxycyclobutane-1-carbaldehyde
• CAS: 156865-33-7
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: PFDGLWBUJWFRJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(benzyloxy)cyclobutane-1-carbaldehyde 在 potassium carbonate 作用下， 以 2,2,2-三氟乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 生成 3-(3-(benzyloxy)cyclobutyl)-1-(4-chloro-2-fluorophenyl)-4-(4-fluorobenzyl)piperazine-2,5-dione
  参考文献：
  名称：

  WO2020047447A5

  摘要：

  公开号：

  WO2020047447A5
• 作为产物：
  描述：

  (3-(benzyloxy)cyclobutyl)methanol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以6.58 g的产率得到3-(benzyloxy)cyclobutane-1-carbaldehyde
  参考文献：
  名称：

  WO2021011913A5

  摘要：

  公开号：

  WO2021011913A5

文献信息

• TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF
  申请人：Shanghai Xiangjin Biotechnology Co., Ltd

  公开号：EP3511327A1

  公开（公告）日：2019-07-17

  The invention discloses a compound with the general formula of (I), wherein, K is selected from: naphthene alkyl and haloalkane alkyl or N-R6. The invention also discloses a tyrosine kinase inhibitor containing the above compound and the application of the compound in preparing drugs for treating cancers. The tyrosine kinase inhibitor of the invention inhibit the bioactivity of multiple signal conduction kinases such as C-MET, VEGF, KDR, etc., it can effectively inhibit cell proliferation and has favorable therapeutic effects on various diseases such as cancer, it has significant therapeutic effects especially on lung cancer, gastric cancer, ovarian cancer, malignant glioma, etc., and it has a very broad application prospect.

  本发明公开了一种通式为（I）的化合物，其中，K 选自：萘烷基 和卤代烷基 或 N-R6。本发明还公开了一种含有上述化合物的酪氨酸激酶抑制剂，以及该化合物在制备治疗癌症药物中的应用。本发明的酪氨酸激酶抑制剂抑制C-MET、VEGF、KDR等多种信号传导激酶的生物活性，能有效抑制细胞增殖，对癌症等多种疾病有良好的治疗作用，尤其对肺癌、胃癌、卵巢癌、恶性胶质瘤等有显著的治疗效果，具有非常广阔的应用前景。
• Tyrosine kinase inhibitor and application thereof
  申请人：LaNova Medicines Limited

  公开号：US10882853B2

  公开（公告）日：2021-01-05

  The invention discloses a compound with the following formula (I), wherein, K is selected from: cycloalkyl and halo alkyl or N—R6. The invention also discloses a tyrosine kinase inhibitor containing the above compound and the use of the compound in preparing drugs for treating cancers. The tyrosine kinase inhibitor of the invention can inhibit the bioactivity of multiple signal conduction kinases such as C-MET, VEGF, KDR, etc., can effectively inhibit cell proliferation and has favorable therapeutic effects on various diseases such as cancer. In particular, the present invention has significant therapeutic effects especially on lung cancer, gastric cancer, ovarian cancer, malignant glioma, etc., and has a very broad application prospect.

  本发明公开了一种具有下式（I）的化合物，其中，K 选自： 环烷基 和卤代烷基 或 N-R6。本发明还公开了一种含有上述化合物的酪氨酸激酶抑制剂以及该化合物在制备治疗癌症药物中的应用。本发明的酪氨酸激酶抑制剂能抑制多种信号传导激酶如 C-MET、VEGF、KDR 等的生物活性，能有效抑制细胞增殖，对癌症等多种疾病具有良好的治疗效果。特别是本发明对肺癌、胃癌、卵巢癌、恶性胶质瘤等具有显著的治疗效果，应用前景十分广阔。
• Cardiac sarcomere inhibitors
  申请人：Cytokinetics, Inc.

  公开号：US11414424B2

  公开（公告）日：2022-08-16

  Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  提供的是式 (I) 化合物： 或其药学上可接受的盐，其中 R1、R2A、R2B、R3、R4 和 R5 如本文所定义。还提供了包含式（I）化合物或其药学上可接受的盐的药学上可接受的组合物。还提供了使用式（I）化合物或其药学上可接受的盐的方法。
• CARDIAC SARCOMERE INHIBITORS
  申请人：Cytokinetics, Inc.

  公开号：EP3843842A1

  公开（公告）日：2021-07-07
• [EN] CARDIAC SARCOMERE INHIBITORS<br/>[FR] INHIBITEURS DE SARCOMES CARDIAQUES
  申请人：CYTOKINETICS INC

  公开号：WO2020047447A1

  公开（公告）日：2020-03-05

  Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.